Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Erste Studie zur Eskalation der menschlichen Dosis zur Bewertung der Sicherheit des TheraSphere Prostate Cancer (PCa)-Geräts (VOYAGER)

29. Oktober 2026 aktualisiert von: Boston Scientific Corporation

Eine frühe Machbarkeitsstudie zur Bewertung der Sicherheit des TheraSphere Prostate Cancer (PCa)-Geräts bei Patienten mit klinisch lokalisiertem Prostatakrebs

The VOYAGER Study is an interventional, non-randomized, single-arm, dose escalation trial with the goal of determining the safety of TheraSphere PCa device in patients with clinically localized prostate cancer across US-based centers.

Studienübersicht

Status

Aktiv, nicht rekrutierend

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

TheraSphere™ Y-90 Glass Microspheres are a targeted cancer therapy consisting of tiny glass beads containing radioactive Yttrium-90 (Y-90), which are injected directly into the blood vessel feeding the tumor through a microcatheter using advanced imaging guidance. The glass microspheres enter the tumor's blood supply, lodge within the blood vessels feeding the tumor, and release radiation to the tumor. The radiation works to destroy the tumor cells from within, thus limiting radiation exposure to surrounding normal tissues, a process referred to as selective internal radiation therapy (SIRT).

This study aims to investigate the maximum safe radiation dose of TheraSphere Prostate Cancer (PCa) device that can be delivered in patients with clinically localized prostate cancer. The study will also evaluate the full safety profile, technical feasibility, efficacy, and quality of life metrics of the TheraSphere PCa device.

Participants will be asked to complete the following:

  • At least two image-guided visits, including a mapping assessment (without Technetium Tc albumin aggregated [Tc-MAA]) prior to treatment
  • One treatment visit, including image-guided assessments
  • Fifteen post-treatment follow-up visits for a total of approximately 20 visits over the 5-year study period

Note: the VOYAGER Study is a staged investigational device exemption (IDE) study; therefore, the full enrollment of 21 to 36 subjects is subject to FDA approval following safety review of the first 10 subjects enrolled.

Studientyp

Interventionell

Einschreibung (Geschätzt)

36

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Illinois
      • Chicago, Illinois, Vereinigte Staaten, 60611
        • Northwestern Memorial Hospital

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

50 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Männlich

Beschreibung

Inclusion Criteria:

  1. Subject has ability to comprehend and willingness to sign and date the IRB-approved study informed consent form (ICF), and to comply with the study testing, procedures, and follow-up schedule.

  2. Histologic confirmation of adenocarcinoma of the prostate by MR-fusion biopsy. Referral biopsy for eligibility must be completed between 180 days and 6 weeks prior to mapping procedure.

  3. Subject with favorable intermediate risk clinically localized prostate cancer defined per NCCN Guidelines version 3.2022 as follows:

    • Favorable intermediate-risk has all the following:

    • i. One Intermediate Risk Factor (IRF):

      1. cT2b-cT2c
      2. Grade Group 2 or 3
      3. PSA 10-20 ng/mL
    • ii. Grade Group 1 or 2

    • iii. <50% biopsy cores positive (e.g., <6 of 12 cores)

  4. Staging MRI must confirm American Joint Committee on Cancer (AJCC, 8th edition) stage T1, T2a, T2b or T2c.

  5. Whole prostate gland volume ≥ 60 cc (measured on MRI)

  6. International Prostate Score Symptom (I-PSS) ≤ 18

  7. Estimated life expectancy of >5 years according to NCCN guideline's tools (NCCN v03.2022) who has declined or is ineligible for Standard of Care treatments (observation, active surveillance, surgery, and radiation therapies [brachytherapy/external beam radiation therapy])

  8. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2

  9. Angiographic inclusion criteria:

    • a. Type I to IV prostate artery origins on both hemiglands.1
    • b. No evidence of procedure limiting vascular abnormalities (aneurysms, stenosis, shunt, fistula, occlusion) or morphologic asymmetric single prostate artery on either side (hemigland)
    • c. Bilaterally accessible solitary prostatic arteries.
    • d. Complete perfusion of the prostate gland via a single dominant vessel for each hemigland
  10. Have adequate organ and bone marrow function within 30 days prior to index procedure, as defined below:

    • a. International Normalized Ratio (INR) ≤ 1.2 (in absence of anticoagulation)
    • b. Platelets ≥ 75,000/L
    • c. GFR ≥ 40 mL/min/1.73m2
    • d. Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L
    • e. Hemoglobin (Hgb) ≥ 9.0 g/dL (Note: the use of transfusion or other intervention to achieve adequate bone marrow function is acceptable
    • f. ALT/AST ≤ 5 x upper limit of normal (ULN)
    • g. Bilirubin ≤ 2 mg/dL
  11. Patients with known Human Immunodeficiency Virus (HIV) infection are eligible with well controlled HIV infection, no current or previous AIDS-related complications and CD4+ T-cell (CD4+) counts ≥ 350 cells/uL

Exclusion Criteria:

  1. Direct evidence of regional or distant metastases after appropriate staging studies per NCCN guidelines (v03.2022)

  2. Histological evidence of intraductal features

  3. Previous treatments (pelvic radiotherapy, surgery, prostate artery embolization [PAE], transurethral resection of the prostate [TURP] or previous/ planned hormonal therapy

  4. History of Crohn's Disease, ulcerative colitis, or ataxia telangiectasia, current gross haematuria, or current urinary catheter

  5. Subjects with ongoing urinary tract infection, prostate abscess, prostatitis, or neurogenic bladder

  6. Prior significant rectal surgery (haemorrhoidectomy is acceptable)

  7. Prior invasive malignancy unless disease free for a minimum of 3 years. Exceptions to this requirement include adequately treated non-melanoma skin cancer or lentigo maligna or carcinoma in situ without evidence of disease

  8. Hip prosthesis

  9. Medical contraindication to undergo contrast-enhanced angiography, CT scan and magnetic resonance imaging (MRI), or arterial catheterization, or known history of hypersensitivity reactions to iodinated and gadolinium-based contrast product

  10. Angiographic exclusion criteria:

    • a. Perfusion to tissues outside the Planning Target Volume (PTV) that cannot be corrected by placement of the catheter distal to collateral vessels or the application of standard angiographic techniques, such as coil embolization
    • b. Type V prostatic artery origin on either side

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Sonstiges
  • Zuteilung: N / A
  • Interventionsmodell: Einzelgruppenzuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: TheraSphere PCa Dose Escalation

Participants will be treated in cohorts of three across three sequential dose levels:

  • Dose Level 1 (or starting dose) = 175 Gy; however, a provisional lower dose level, Dose Level -1 = 150 Gy, may be utilized in case de-escalation is warranted at Dose Level 1.
  • Dose Level 2 = 200 Gy
  • Dose Level 3 = 225 Gy

Single session treatment of TheraSphere PCa - Yttrium-90 Glass Microspheres for the treatment of prostate cancer. Dose vials will be available in activity ranging from 0.1 GBq (2.7 mCi) to 3 GBq (81 mCi).

Andere Namen:
  • TheraSphere PCa – Yttrium-90-Glasmikrokugeln

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Maximum tolerated radiation dose of TheraSphere PCa
Zeitfenster: Through 90 days post-treatment

• The Maximum Tolerated Dose (MTD) of Yttrium-90 Glass Microspheres (TheraSphere™ PCa) is based on rate of dose limiting toxicity (DLT) through 90 days, defined as any ≥ grade 3 adverse event (AE) according to CTCAE v.5

Through 90 days post-treatment

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Incidence of adverse events (AEs)
Zeitfenster: Through 5 years post-treatment (acute ≤ 90 days and late > 90 days)

The following AEs/SAEs will be assessed in accordance with National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0:

  • Rate of any ≥ grade 3 AEs
  • Rate of AEs of interest, i.e., any ≥ Grade 2 GI/GU and erectile dysfunction toxicities
  • Rate of any treatment-emergent AEs and treatment-emergent SAEs
  • Rate of any treatment-related AEs and treatment-related SAEs
  • AEs related to non-target TheraSphere PCa distribution
Through 5 years post-treatment (acute ≤ 90 days and late > 90 days)
Rate of success of delivering intended dose
Zeitfenster: Immediately post-treatment

• The ability to deliver the intended TheraSphere PCa absorbed dose (+/- 20%) to the treatment volume based on post-treatment PET derived absorbed dose.

Immediately post-treatment
Recurrence Free Survival
Zeitfenster: Through 5 years post-treatment

• Biochemical Recurrence Free Survival (bRFS) based on PSA according to the Phoenix criteria (RTOG-ASTRO definition). Biochemical recurrence of prostate cancer after curative treatment is defined as a PSA rise of ≥ 2 ng/mL above the post-treatment nadir.

Through 5 years post-treatment
Progression free survival (PFS)
Zeitfenster: Through 5 years post-treatment

• Progression free survival (PFS) and local progression free survival (LPFS), defined as time from inclusion until one of the following events, whichever comes first: biochemical progression (Phoenix criteria) or clinical progression.

Through 5 years post-treatment
Prostate cancer specific survival
Zeitfenster: Through 5 years post-treatment

• Prostate cancer specific survival will be measured as the number of days between treatment with TheraSphere PCa and death by prostate cancer.

Through 5 years post-treatment
Overall survival (OS)
Zeitfenster: Through 5 years post-treatment

• OS will be measured as the number of days between treatment with TheraSphere PCa and death by any cause.

Through 5 years post-treatment
Rate of subsequent prostate anticancer treatment
Zeitfenster: Through 5 years post-treatment

• A summary table with number of subjects (%) who received subsequent definitive or systematic therapy and type of therapies received will be presented.

Through 5 years post-treatment
Rate of histopathological recurrence
Zeitfenster: Through 5 years post-treatment

• Rate of recurrence based on histopathological assessment of prostate MR/US-fusion biopsy in patients with evidence of progression.

Through 5 years post-treatment
Quality of Life (QoL) measured by EPIC-26
Zeitfenster: Through 5 years post-treatment

• Change from baseline measured through Expanded Prostate Cancer Index Composite (EPIC-26).

Through 5 years post-treatment
Quality of Life (QoL) measured by MSHQ
Zeitfenster: Through 5 years post-treatment

• Change from baseline measured through Male Sexual Health Questionnaire (MSHQ).

Through 5 years post-treatment
Quality of Life (QoL) measured by I-PSS
Zeitfenster: Through 5 years post-treatment

• Change from baseline measured through International Prostate Symptom Score (I-PSS).

Through 5 years post-treatment
Maximum urinary flow (Qmax)
Zeitfenster: Through 5 years post-treatment

• Change from baseline

Through 5 years post-treatment
Post-void residual (PVR) urine test
Zeitfenster: Through 5 years post-treatment

• Change from baseline

Through 5 years post-treatment
Dose Distribution
Zeitfenster: Through one-week post-treatment

• Dose Volume Histogram (DVH) and evaluation of D90 from post-treatment Y90 PET-MRI/CT.

Through one-week post-treatment

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Prostatic imaging assessment
Zeitfenster: Through 5 years post-treatment

• Qualitative analysis of multi-parametric MRI (mp-MRI) and PI-RADS score

Through 5 years post-treatment

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: Samdeep Mouli, M.D., M.S., Northwestern Medical Hospital
  • Hauptermittler: Mark Hurwitz, MD, Westchester Medical Center

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

15. April 2024

Primärer Abschluss (Geschätzt)

1. Januar 2028

Studienabschluss (Geschätzt)

1. Oktober 2032

Studienanmeldedaten

Zuerst eingereicht

28. November 2023

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

21. Dezember 2023

Zuerst gepostet (Tatsächlich)

5. Januar 2024

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

30. Oktober 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

29. Oktober 2026

Zuletzt verifiziert

1. Oktober 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • S2493

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Ja

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren